Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance

Financial Performance - Generated net product revenue of $68.1 million from sales of LUMRYZ, representing a 64% increase compared to $41.5 million for the same period in 2024 [6][10] - Achieved net income of $9.7 million, or $0.10 per diluted share, compared to a net loss of $13.8 million, or ($0.14) per diluted share, for the same period in 2024 [12][10] - Positive cash flow in the quarter ended June 30, 2025, with cash, cash equivalents, and marketable securities increasing by $15.0 million compared to March 31, 2025 [13][6] Patient Growth and Market Position - As of June 30, 2025, 3,100 patients were being treated with LUMRYZ, a 63% increase compared to 1,900 patients as of June 30, 2024 [6][3] - The company raised its full-year revenue guidance for 2025 to a range of $265 - $275 million [6][3] Regulatory and Clinical Developments - Received Orphan Drug Designation from the FDA for LUMRYZ for the treatment of Idiopathic Hypersomnia (IH) [6][3] - On track to complete enrollment in the pivotal Phase 3 REVITALYZ study evaluating the efficacy and safety of LUMRYZ in IH by the end of 2025 [6][3] Corporate Updates - Appointed Susan Rodriguez as Chief Operating Officer to oversee commercial strategy, operations, and supply chain [6][3] - The U.S. Court of Appeals affirmed the FDA's approval of LUMRYZ for patients seven years of age and older with narcolepsy, noting its clinical superiority [7][6]